Why Acne Has Never Had a Vaccine Until Now
Acne affects millions of teenagers and young adults around the world. It shows up as pimples, blackheads, and cysts on the face, back, and chest. A main cause is a bacterium named Cutibacterium acnes, or C. acnes for short. This germ lives on our skin and can trigger swelling and block pores when it grows too much. For years, doctors treated acne with creams, pills, and antibiotics. But these often fail to fix the root problem. They can also cause dry skin, irritation, or resistance to antibiotics over time.
Scientists tried to make vaccines against C. acnes before. Early ideas focused on killing the germ completely. But that did not work well. Our skin needs some C. acnes to stay healthy. It helps control other bad germs and keeps the skin barrier strong. A vaccine that wipes it out could upset this balance and lead to new skin issues. Plus, different people have different types of C. acnes. Some strains cause acne while others do not. Matching a vaccine to all versions proved hard.
Tech advances changed this. New tools like mRNA let experts target just the bad parts of the germ. mRNA vaccines teach the body to fight specific proteins from C. acnes without harming good bacteria. They promise fewer side effects than old drugs.
Now, vaccines are finally in real tests. In late 2025, Immorna Biotechnology got FDA approval to start a Phase 1/2 trial for their shot called JCXH-401. It uses mRNA to hit two key targets in C. acnes. The trial starts with adults who have moderate to severe acne. Sanofi has another mRNA candidate in Phase 2 trials. These are the only two acne mRNA vaccines worldwide right now. Pfizer wrapped up an early acne trial in 2024, hinting at more work in skin treatments.
Experts see hope here. Past research on acne vaccines kept going in the background, but mRNA made them practical. If trials succeed, people could get a one-time shot instead of lifelong creams or pills.
Sources
http://www.immornabio.com/investors-detail-244.html
https://catalystalert.io/drug/b4e024b2-fc3e-42ad-8c51-a497e074a857
https://www.stocktitan.net/news/SGMT/sagimet-s-license-partner-ascletis-announced-acceptance-of-new-drug-my9wyvmm6620.html
https://clinicaltrials.gov/study/NCT07296523
https://blogs.the-hospitalist.org/topics/acne
https://www.tipranks.com/news/company-announcements/pfizer-completes-early-stage-acne-trial-signaling-quiet-expansion-in-dermatology
https://directivepublications.org/advances-in-vaccines
